- Home
- STXS vs CNTX Comparison
STXS vs CNTX Comparison
Compare STXS & CNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STXS
- CNTX
- Stock Information
- Founded
- STXS 1990
- CNTX 2015
- Country
- STXS United States
- CNTX United States
- Employees
- STXS N/A
- CNTX N/A
- Industry
- STXS Biotechnology: Electromedical & Electrotherapeutic Apparatus
- CNTX Biotechnology: Pharmaceutical Preparations
- Sector
- STXS Health Care
- CNTX Health Care
- Exchange
- STXS Nasdaq
- CNTX Nasdaq
- Market Cap
- STXS 173.5M
- CNTX 149.6M
- IPO Year
- STXS 2004
- CNTX 2021
- Fundamental
- Price
- STXS $2.10
- CNTX $1.50
- Analyst Decision
- STXS Strong Buy
- CNTX Strong Buy
- Analyst Count
- STXS 2
- CNTX 3
- Target Price
- STXS $4.50
- CNTX $6.83
- AVG Volume (30 Days)
- STXS 332.6K
- CNTX 210.1K
- Earning Date
- STXS 11-11-2024
- CNTX 11-06-2024
- Dividend Yield
- STXS N/A
- CNTX N/A
- EPS Growth
- STXS N/A
- CNTX N/A
- EPS
- STXS N/A
- CNTX N/A
- Revenue
- STXS $25,143,000.00
- CNTX N/A
- Revenue This Year
- STXS $1.16
- CNTX N/A
- Revenue Next Year
- STXS $55.65
- CNTX N/A
- P/E Ratio
- STXS N/A
- CNTX N/A
- Revenue Growth
- STXS N/A
- CNTX N/A
- 52 Week Low
- STXS $1.51
- CNTX $0.77
- 52 Week High
- STXS $3.29
- CNTX $2.75
- Technical
- Relative Strength Index (RSI)
- STXS 53.19
- CNTX 25.94
- Support Level
- STXS $1.96
- CNTX $1.56
- Resistance Level
- STXS $2.12
- CNTX $2.32
- Average True Range (ATR)
- STXS 0.12
- CNTX 0.16
- MACD
- STXS 0.01
- CNTX -0.07
- Stochastic Oscillator
- STXS 50.00
- CNTX 17.88
About STXS Stereotaxis Inc.
Stereotaxis Inc is engaged in robotic technologies designed to enhance the treatment of arrhythmias and perform endovascular procedures. The company's mission is the discovery, development, and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide patient care with robotic precision and safety, improved lab efficiency and productivity, and enhanced integration of procedural information. The company's revenue generation is derived from the streams of Systems; Disposables, Royalty; and Sublease, of which a majority of revenue is generated from the Disposables, service and accessories stream. The company generates the majority of revenue from the United States.
About CNTX Context Therapeutics Inc.
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of innovative therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 ("CLDN6") x anti-CD3 bispecific antibody ("bsAb") that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.